Purpose: Neoadjuvant chemotherapy (NCT) is a treatment modality that increases the breast-conserving rate in breast cancer. This prospective study was performed to evaluate the actual breast-conserving rate using NCT in a clinical setting in a single institution. Methods: Between 2014 and 2015, 265 patients who were scheduled to receive NCT and surgery were enrolled in this study. Patients were classified into three groups based on the immunohistochemical results of estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2): ER or PR positive (luminal), ER/PR negative and HER2 positive (HER2+), and triple-negative breast cancer (TNBC). Before starting and immediately after completing NCT, a surgeon decided if breast-conserving surgery (BCS) or total mastectomy (TM) should be performed. We analyzed the rate of type of surgery performed. Results: Before administering NCT, 107 patients (40.4%) and 158 patients (59.6%) were candidates for BCS and TM, respectively. Of the 158 patients, 61 were eligible for BCS after chemotherapy, with a conversion rate of 38.6%. NCT increased the BCS eligible rate from 40.4% to 62.6%. Of the 61 patients, 53 chose to undergo BCS, and BCS was successful in 46 (86.8%). Of the 107 BCS candidates at baseline, 100 patents finally underwent BCS (93.5%). According to the subtype, the conversion rates were 35.4%, 50.0%, and 40.5% for luminal, HER2+, and TNBC groups, respectively. Conclusion: NCT increased the eligibility for BCS from 40.4% to 62.6% in a clinical setting. This benefit is similar to that observed in other clinical trials.
INTRODUCTION
Neoadjuvant chemotherapy (NCT) is a widely used treatment modality for early and locally advanced breast cancer because it increases the likelihood of breast-conserving surgery (BCS) [1] . Several studies have investigated the oncologic safety and the extent to which NCT can actually convert total mastectomy (TM) candidates to BCS candidates [2] . The results implicate that NCT may improve the patients' quality of life by allowing BCS in as many patients as possible [3] .
However, most of the studies showing the benefit of NCT in increasing the BCS rate were retrospective analyses conducted in patients enrolled in clinical trials that test the efficacy of NCT [4] [5] [6] . Recently, Golshan et al. [2] published the results from two prospective studies on the impact of NCT on BCS eligibility and BCS rate in triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer as companion studies to the CALGB40603 and 40601 trials [7] . They showed that NCT results in 14% and 23% absolute BCS eligibility increase in TNBC and HER2-positive patients, respectively.
In this study, by analyzing patients undergoing NCT and surgery in a single institution, the effects of NCT on the conversion from TM to BCS were prospectively examined in a routine clinical setting. Moreover, we attempted to determine the difference in the conversion rate based on the intrinsic subtype of breast cancer.
METHODS
Patients with clinical stage II or III primary breast cancer who were scheduled for NCT before surgery during the study period were included. Patients who did not complete the full cycles of NCT due to ORIGINAL ARTICLE 52 Hyejin Mo, et al. toxicity or disease progression were included in the analysis (n =12).
Finally, 265 patients were enrolled. Table 1 shows the regimens used for patients who completed NCT as scheduled. The most common regimen (92.9%) was four cycles of doxorubicin/cyclophosphamide, followed by four cycles of taxane with or without trastuzumab. 
RESULTS
Of the 265 patients, 107 (40.4%) were BCS and 158 (59.6%) were TM candidates before initiating NCT. Table 2 shows the patients' demographics.
After NCT, 61 of the 158 TM candidates were converted to BCS candidates, with the conversion rate of 38.6% ( Figure 1 ). Based on the subtype, the conversion rate was 35.4% (34/96), 50.0% (10/20), and 40.5% (17/42) among patients with the luminal, HER2+, and TNBC, respectively. The absolute increase in BCS eligibility was 22.2% (from The tumor size and BCS conversion rate were inversely correlated.
The larger the initial tumor size before NCT, the lower was the BCS conversion rate (Figure 2 
DISCUSSION
NCT results in surgical downstaging of tumors and allows breast conservation in women who otherwise would have needed mastectomy. In the NSABP B-18 study, NCT was associated with a higher rate of BCS (68% vs. 60%, p = 0.001) than adjuvant chemotherapy [8] . In the EORTC 10902 trial, the breast conservation rates were 35% and 22% in the neoadjuvant and adjuvant arm, respectively [9] . A prospective study by Golshan et al. [2] for TNBC (CALGB40603) showed a 42% conversion rate from BCS-ineligible to BCS-eligible patients, resulting in a 14% absolute increase in BCS eligibility. In another study on HER2-positive breast cancer (CALGB40601) by the same authors, NCT increased the BCS-eligibility rate from 41% to 64% [2, 7] .
To the best of our knowledge, this is the first prospective study that investigated the change in BCS eligibility with NCT in a clinical setting, but not in a clinical trial. In this study, the conversion rate from BCS to TM as a result of NCT using routine chemotherapy regimens was 38.6%, which is similar to that observed in other previous studies.
The absolute increase in BCS eligibility was 22.2%, which is superior to that noted in the CALGB40603 study for TNBC. The increase in BCS eligibility is more noteworthy because different subtypes were evaluated in our cohort, including the luminal type. The response to NCT is worse in luminal subtype breast cancer patients [10] . In the present study, the pathologic complete response rate of the luminal type group was 14.7%, which is lower than that of the other two groups (27.5%).
Safety concerns regarding BCS after NCT have been raised. The meta-analysis by Mieog et al. [6] showed that the rates of local or regional recurrences in patients who underwent neoadjuvant versus adjuvant therapy were not different when stratified based on the type of surgery. They also found no difference in locoregional recurrences for patients who were scheduled to undergo BCS and those who were downstaged to BCS candidates. Similarly, this study showed that BCS after NCT in clinical stage III patients is oncologically safe in terms of local recurrence. The rate of local recurrence-free survival was not different between the surgery-first, preplanned BCS, and downstaged BCS groups [11] .
In the CALGB40603 study by Golshan et al. [2] , BCS was not A limitation of our study was that determining whether a patient will be a BCS or TM candidate was not always feasible. A significant proportion of the patients had borderline possibility of BCS. In particular, judgments about poor cosmesis may be different for each surgeon; thus, this should be considered in interpreting the results.
In conclusion, NCT increased the eligibility for BCS from 40.4% to 62.6% in our prospective study conducted in a clinical setting. This benefit is similar to that obtained in previous clinical trials. The rate for attempting BCS was higher in our study than that in previous multicenter clinical trials.
